Trial Profile

Arimoclomol Prospective Double-blind, Randomised, Placebo-controlled Study in Patients Diagnosed With Niemann-Pick Disease Type C

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 25 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Arimoclomol (Primary)
Indications Niemann-Pick disease type C
Focus Registrational; Therapeutic Use
Sponsors Orphazyme; Zevra Therapeutics

Most Recent Events

21 Apr 2025 According to a Zevra Therapeutics Media release, the company has recently sold the Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million to further enhance financial flexibility.
30 Jan 2025 According to a Zevra Therapeutics Media release, data from the study has been accepted for the presentation at the 21st Annual WORLDSymposium™.
28 Nov 2024 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com